The 16th World ADC London, February 23–26, 2026, London, United Kingdom, set to take place at ExCeL London, will once again unite global leaders in the Antibody-Drug Conjugate (ADC) field. Recognized as Europe’s premier ADC-focused event, the 2026 edition will emphasize differentiation across every stage of the ADC value chain , from molecular design to large-scale production.
Focus on Differentiation and Resistance Challenges
The 2026 meeting arrives at a pivotal moment for the ADC field, as the widespread use of Topo1 and MMAE payloads raises concerns about therapeutic resistance and limits in innovation. This year’s central theme, differentiation across the ADC value chain aims to address these challenges by exploring novel payload classes, alternative conjugation strategies, and next-generation targeting mechanisms.
Comprehensive Program and Scientific Streams
Over four days, participants will gain insights through five dedicated content streams that cover the full lifecycle of ADC development. Topics include novel cytotoxic and non-cytotoxic payloads, dual and bispecific ADCs, and non-antibody conjugates, along with strategies to integrate ADCs into earlier-line oncology settings for maximum patient impact.
The program is designed to bridge preclinical discovery, manufacturing, and clinical application, ensuring a holistic perspective on the evolution of targeted cancer therapies.
Global Participation and Networking Opportunities
The 16th World ADC London will host more than 800 industry attendees representing over 240 companies, featuring a distinguished faculty of 120 global speakers. Delegates will benefit from 14+ hours of networking, including one-on-one partnering sessions, informal networking receptions, and panel discussions that foster collaboration between academia, biopharma, and regulatory experts.
Advancing the Future of ADC Development
With its five tracks of end-to-end ADC content, World ADC London continues to serve as the leading platform for scientific exchange, business development, and strategic collaboration. The event remains instrumental in shaping the future of targeted cancer therapy, driving innovation and excellence across the global ADC ecosystem.
Event Details
Dates: February 23–26, 2026
Venue: ExCeL London, United Kingdom
Attendees: 800+ ADC industry professionals
Companies: 240+ organizations represented
Speakers: 120+ global experts
Networking: 14+ hours of formal and informal opportunities
For more details
Explore more updates and insights on ADCs at OncoDaily.com